ProShare Advisors
EVH icon

ProShare Advisors’s Evolent Health EVH Stock Holding History

ProShare Advisors’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.3K Sell
15,001
-1,173
-7% -$4.5K ﹤0.01% 1801
2026
Q1 		$36.9K Sell
16,174
-5,275
-25% -$16.7K ﹤0.01% 1808
2025
Q4 		$85.8K Buy
21,449
+1,381
+7% +$7.68K ﹤0.01% 1894
2025
Q3 		$170K Sell
20,068
-3,998
-17% -$38.8K ﹤0.01% 1734
2025
Q2 		$271K Sell
24,066
-925
-4% -$8.5K ﹤0.01% 1518
2025
Q1 		$237K Sell
24,991
-7,522
-23% -$76K ﹤0.01% 1571
2024
Q4 		$366K Buy
32,513
+10,698
+49% +$188K ﹤0.01% 1482
2024
Q3 		$617K Buy
21,815
+6,758
+45% +$174K ﹤0.01% 1016
2024
Q2 		$288K Sell
15,057
-5,141
-25% -$131K ﹤0.01% 1316
2024
Q1 		$662K Buy
20,198
+1,962
+11% +$62.6K ﹤0.01% 937
2023
Q4 		$602K Buy
18,236
+3,924
+27% +$111K ﹤0.01% 936
2023
Q3 		$390K Sell
14,312
-17
-0.1% -$473 ﹤0.01% 1049
2023
Q2 		$434K Buy
14,329
+4,680
+49% +$151K ﹤0.01% 1034
2023
Q1 		$313K Sell
9,649
-900
-9% -$28.5K ﹤0.01% 1191
2022
Q4 		$296K Buy
10,549
+1,512
+17% +$43.3K ﹤0.01% 1240
2022
Q3 		$324K Sell
9,037
-172
-2% -$6.06K ﹤0.01% 1104
2022
Q2 		$283K Sell
9,209
-5,746
-38% -$167K ﹤0.01% 1247
2022
Q1 		$483K Sell
14,955
-2,458
-14% -$64.4K ﹤0.01% 1296
2021
Q4 		$481K Buy
17,413
+7,480
+75% +$215K ﹤0.01% 1478
2021
Q3 		$308K Sell
9,933
-10,177
-51% -$244K ﹤0.01% 1525
2021
Q2 		$425K Sell
20,110
-66
-0.3% -$1.32K ﹤0.01% 1646
2021
Q1 		$408K Buy
20,176
+3,451
+21% +$65.6K ﹤0.01% 1580
2020
Q4 		$268K Buy
+16,725
New +$221K ﹤0.01% 1679
2020
Q3 		– Sell
-10,261
Closed -$73K – 1659
2020
Q2 		$73K Buy
+10,261
New +$68.7K ﹤0.01% 1606
2020
Q1 		– Sell
-10,042
Closed -$91K – 1301
2019
Q4 		$91K Buy
+10,042
New +$81.6K ﹤0.01% 1703
2018
Q4 		– Sell
-8,339
Closed -$237K – 1617
2018
Q3 		$237K Buy
+8,339
New +$199K ﹤0.01% 1492

Other funds holding EVH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

ProShare Advisors's EVH Position: Q2 2026 in Review

ProShare Advisors reduced its Evolent Health (EVH) stake by 7.3% in Q2 2026, selling an estimated $4.5K and leaving 15,001 shares worth $81.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1801.

ProShare Advisors first reported a position in EVH in Q3 2018 and has held it in 26 quarters since. The position peaked at $662K in Q1 2024. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

  • ProShare Advisors held 15,001 shares of Evolent Health worth $81.3K as of Q2 2026.
  • ProShare Advisors sold 1,173 Evolent Health shares in Q2 2026, an estimated $4.5K.
  • Evolent Health made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1801 holding.
  • ProShare Advisors first reported a position in Evolent Health in Q3 2018 and has held it in 26 quarters since.
  • ProShare Advisors's Evolent Health position peaked at $662K in Q1 2024.
  • 199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.